<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531046</url>
  </required_header>
  <id_info>
    <org_study_id>ALYCANTE</org_study_id>
    <nct_id>NCT04531046</nct_id>
  </id_info>
  <brief_title>Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation</brief_title>
  <official_title>Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel)&#xD;
      as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are&#xD;
      ineligible to receive Autologous Stem Cell Transplantation but eligible to receive CAR T-cell&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy&#xD;
      directed against CD19 which has been approved for the treatment of relapse/refractory diffuse&#xD;
      large B-cell lymphoma DLBCL and primary mediastinal large B-cell lymphoma (PMBCL) after 2 or&#xD;
      more lines of systemic therapy.&#xD;
&#xD;
      But administrating CAR T-cells earlier in the therapeutic strategy may be beneficial to&#xD;
      patients.&#xD;
&#xD;
      Axi-cel will improve the outcome of patients with DLBCL who are refractory or relapse early&#xD;
      (i.e. within 1 year from end of treatment) after first-line therapy and who are not eligible&#xD;
      for Autologous Stem Cell Transplantation (ASCT).&#xD;
&#xD;
      Transplant-ineligible patients will include those who are deemed ineligible for high-dose&#xD;
      chemotherapy and Hematopoietic Stem Cell Transplantation (HSCT) due to age, comorbidity, or&#xD;
      prior ASCT.&#xD;
&#xD;
      The primary endpoint will be complete metabolic response (CMR) at 3 months after Axi-cel&#xD;
      infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open-label, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Metabolic Response (CMR) - determined by investigator</measure>
    <time_frame>3 months from axi-cel infusion</time_frame>
    <description>CMR from axi-cel infusion (without additional anticancer therapy) based on investigator disease assessment according to PET-scan (using the Lugano Response Criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Metabolic Response (CMR) - determined by central imaging review</measure>
    <time_frame>3 months from axi-cel infusion</time_frame>
    <description>CMR from axi-cel infusion (without additional anticancer therapy) determined by central imaging review (using the Lugano Response Criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response</measure>
    <time_frame>between Day 14 and Month 12</time_frame>
    <description>Percentage of CMR and Partial MR determined by investigator disease assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAE)</measure>
    <time_frame>at 30 days after axi-cel infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) based on investigator disease assessment</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) based on investigator disease assessment</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) based on investigator disease assessment</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) based on central imaging review</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) based on central imaging review</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) based on central imaging review</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified EFS (mEFS) based on investigator assessment</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified EFS (mEFS) based on investigator assessment</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified EFS (mEFS) based on central imaging review</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified EFS (mEFS) based on central imaging review</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response</measure>
    <time_frame>at 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>at 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) from leukaphaeresis and Axi-cel infusion</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) from leukaphaeresis and Axi-cel infusion</measure>
    <time_frame>at 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>B-Cell Lymphoma Refractory</condition>
  <condition>B-cell Lymphoma Recurrent</condition>
  <arm_group>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>axicabtagene ciloleucel</intervention_name>
    <description>Patient-specific (autologous) product cryopreserved in cryostorage bag</description>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
    <other_name>axi-cel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who understands and speaks one of the country official languages and signed&#xD;
             Informed Consent Form&#xD;
&#xD;
          -  Histologically proven relapsed or refractory aggressive B-cell non-Hodgkin lymphoma&#xD;
             (B-NHL) of the following histology at relapse: diffuse large B-cell lymphoma (DLBCL),&#xD;
             high-grade B-cell lymphoma (HGBL), follicular lymphoma Grade 3B per World Health&#xD;
             Organization (WHO) 2016 classification and Primary mediastinal Bcell lymphomas.&#xD;
             Indolent B-NHL who transformed into aggressive B-NHL and were previously treated with&#xD;
             Rituximab-Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP) are&#xD;
             eligible.&#xD;
&#xD;
          -  Tumoral tissue (at diagnosis or relapse) available for central pathology review,&#xD;
             exploratory endpoints and ancillary studies&#xD;
&#xD;
          -  Positron-emission tomography (PET)-positive disease&#xD;
&#xD;
          -  Patients must have received adequate first-line therapy including at a minimum: an&#xD;
             anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and Cyclophosphamide,&#xD;
             Hydroxydaunomycin, Oncovin, and Prednisone (CHOP) or CHOP-like chemotherapy&#xD;
&#xD;
          -  Relapsed or refractory disease after first-line chemoimmunotherapy (full dose of&#xD;
             R-CHOP or R-CHOP-like regimen), documented by PET-scan&#xD;
&#xD;
          -  At least 2 weeks must have elapsed since any prior systemic cancer therapy at the time&#xD;
             the patient provides consent&#xD;
&#xD;
          -  Patients must be autologous stem cell transplantation (ASCT)-ineligible&#xD;
&#xD;
          -  Patients must be CAR-T-eligible&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             (females who have undergone surgical sterilization or who have been postmenopausal for&#xD;
             at least 12 months are not considered to be of childbearing potential)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who received more than one prior line of systemic therapy&#xD;
&#xD;
          -  Patients who are intolerant to first-line therapy or who received suboptimal&#xD;
             first-line therapy, including dose-reduced R-CHOP (&quot;R-miniCHOP&quot;), and those who&#xD;
             discontinued prematurely first-line therapy due to toxicity are not eligible&#xD;
&#xD;
          -  Prior CD19 targeted therapy&#xD;
&#xD;
          -  Patients with cardiac atrial or cardiac ventricular lymphoma involvement&#xD;
&#xD;
          -  Requirement for urgent therapy due to tumor mass effects, such as bowel obstruction or&#xD;
             blood vessel compression&#xD;
&#xD;
          -  Patient with clinically significant pleural effusion&#xD;
&#xD;
          -  History of another primary malignancy that has not been in remission for at least 2&#xD;
             years (except for nonmelanoma skin cancer or carcinoma in situ (eg, cervix, bladder,&#xD;
             breast))&#xD;
&#xD;
          -  Patients with detectable Central Nervous System (CNS) lymphoma&#xD;
&#xD;
          -  History or presence of non-malignant CNS disorder, such as seizure disorder requiring&#xD;
             anti-convulsive therapy, cerebellar disease, or any autoimmune disease with CNS&#xD;
             involvement disease&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection, positive serology of human&#xD;
             immunodeficiency virus (HIV) and syphilis at the time of screening&#xD;
&#xD;
          -  Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate&#xD;
             antibiotics or other treatment at the time of leukapheresis or axi-cel administration&#xD;
&#xD;
          -  History of any one of the following cardiovascular conditions within the past 6&#xD;
             months: Class III or IV heart failure as defined by the New York Heart Association,&#xD;
             cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other&#xD;
             clinically significant cardiac disease&#xD;
&#xD;
          -  History of autoimmune disease requiring systemic immunosuppression and/or systemic&#xD;
             disease modifying agents within the last year&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest&#xD;
             computed tomography (CT) scan at screening.&#xD;
&#xD;
          -  History of severe immediate hypersensitivity reaction to tocilizumab or any of the&#xD;
             agents used in this study&#xD;
&#xD;
          -  History of severe immediate hypersensitivity reaction attributed to aminoglycosides,&#xD;
             cyclophosphamide and fludarabine&#xD;
&#xD;
          -  Treatment with a live, attenuated vaccine within 6 weeks prior to initiation of study&#xD;
             treatment or anticipation of need for such a vaccine during the course of the study&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant or breastfeeding (from the time of&#xD;
             consent during treatment and for at least 6 months after conditioning chemotherapy&#xD;
             dosing or axicabtagene ciloleucel dosing, whichever is later)&#xD;
&#xD;
          -  In the investigator's judgment, the patient is unlikely to complete all&#xD;
             protocol-required study visits or procedures, including follow-up visits, or comply&#xD;
             with the study requirements for participation&#xD;
&#xD;
          -  Adult person unable to provide informed consent because of intellectual impairment,&#xD;
             any serious medical condition, laboratory abnormality or psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roch Houot, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital, Rennes, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Lemonnier, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henri Mondor Hospital, Créteil, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Véronique Vacher</last_name>
    <phone>+33 (0)4 27 01 27 14</phone>
    <email>veronique.vacher@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Bonnet, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe BONNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Xavier GROS</last_name>
    </contact>
    <investigator>
      <last_name>François-Xavier GROS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand - Hôpital Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BAY</last_name>
    </contact>
    <investigator>
      <last_name>Olivier BAY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François LEMONNIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Hôpital le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, MD</last_name>
      <email>f-morschhauser@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck MORSCHHAUSER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CARTRON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume CARTRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven LE GOUILL, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Thieblemont, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Pitié Salpétriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Choquet</last_name>
      <phone>+33 (0)1 42 16 28 26</phone>
      <email>sylvain.choquet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rémy DULERY</last_name>
    </contact>
    <investigator>
      <last_name>Rémy DULERY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel BACHY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roch HOUOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie OBERIC</last_name>
    </contact>
    <investigator>
      <last_name>Lucie OBERIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FEUGIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre FEUGIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina CASTILLA LLORENTE</last_name>
    </contact>
    <investigator>
      <last_name>Cristina CASTILLA LLORENTE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

